RXRX – recursion pharmaceuticals, inc. - class a (US:NASDAQ)
Stock Stats
News
Familial Adenomatous Polyposis Pipeline Landscape Report 2024 [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $11.00 price target on the stock.
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion and Exscientia Shareholders Approve the Proposed Combination
Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden
Form 144 RECURSION PHARMACEUTICAL Filed by: Marriott Tina
Form 8-K RECURSION PHARMACEUTICAL For: Nov 19
Form S-8 RECURSION PHARMACEUTICAL
Form 4 RECURSION PHARMACEUTICAL For: Nov 15 Filed by: Mauro David J
Form 4 RECURSION PHARMACEUTICAL For: Nov 15 Filed by: Gibson Christopher
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.